NLS Pharmaceutics (NASDAQ:NCEL) vs. USANA Health Sciences (NYSE:USNA) Head to Head Review

USANA Health Sciences (NYSE:USNA) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Institutional & Insider Ownership

54.3% of USANA Health Sciences shares are held by institutional investors. 0.6% of USANA Health Sciences shares are held by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for USANA Health Sciences and NLS Pharmaceutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
USANA Health Sciences	1	3	0	0	1.75
NLS Pharmaceutics	1	0	0	0	1.00

USANA Health Sciences currently has a consensus price target of $36.00, indicating a potential upside of 76.99%. Given USANA Health Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe USANA Health Sciences is more favorable than NLS Pharmaceutics.

Valuation and Earnings

This table compares USANA Health Sciences and NLS Pharmaceutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
USANA Health Sciences	$912.67 million	0.41	$42.03 million	$0.88	23.11
NLS Pharmaceutics	N/A	N/A	-$1.98 million	N/A	N/A

USANA Health Sciences has higher revenue and earnings than NLS Pharmaceutics.

Profitability

This table compares USANA Health Sciences and NLS Pharmaceutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
USANA Health Sciences	1.86%	6.97%	5.00%
NLS Pharmaceutics	N/A	N/A	N/A

Volatility and Risk

USANA Health Sciences has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500.

Summary

USANA Health Sciences beats NLS Pharmaceutics on 9 of the 10 factors compared between the two stocks.

About USANA Health Sciences

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

About NLS Pharmaceutics

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.